ClinicalTrials.gg
CompletedNCT05470751Updated Apr 30, 2024

GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology

An observational study in Bladder Outlet Obstruction, Multiple Sclerosis and Cauda Equina Syndrome, sponsored by ConvaTec Inc.. Completed at 16 sites in 3 countries. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by ConvaTec Inc. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
72
Ages
18 Years to 100 Years
Sex
Male
01

Study summary

Male self catherterisng observational study.

Read the detailed description

This is a multicentre, prospective international observational study. Male patients in the UK, USA and France performing self-catheterisation will be asked to participate in this study. The subjects will be asked to use the GentleCath™ Intermittent Catheter with FeelClean™ Technology as per their normal routine. They will be asked to record when and where they catheterise. At the baseline, during and on completion of the study, the subjects will be asked to complete Difficulty in Catheterisation plus Intermittent Catheter related Quality of Life Questionnaires.

Difficulty during catheterisation and quality of life will be assessed using the ICDQ and ISC-Q validated questionnaires during catheterisation at the start of the study before use of GentleCath™ Air has commenced (D0) and on day 1 (D1), day 15 (D15), day 30 (D30), day 45 (D45) and day 60 (D60) transcribed in a collecting record provided for this purpose. Compliance and catheter use will also be assessed.

Patient confidence regarding reduced stickiness plus related risk of urethral injury and resultant bleeding or infection will also be recorded.

02

Conditions studied

  • Bladder Outlet Obstruction
  • Multiple Sclerosis
  • Cauda Equina Syndrome
  • Enlarged Prostate With Lower Urinary Tract Symptoms
  • Parkinson Disease
  • Lower Urinary Tract Symptoms
  • Detrusor Underactivity
  • Spinal Cord Injuries

Keywords

  • neurogenic bladder
  • intermittent self-catherterisation
  • pain
  • bladder outflow obstruction
03

In context

Urinary Bladder Neck Obstruction

42 studies on the registry are indexed under Urinary Bladder Neck Obstruction; 10 are open to participants now.

This study's enrollment of 72 is below the median of 165 across 14 observational studies indexed under Urinary Bladder Neck Obstruction.

Browse Urinary Bladder Neck Obstruction studies →

Lead sponsor

ConvaTec Inc. is the lead sponsor of 46 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult males who self-catheterise

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Adult male (aged 18 years and over)

      • Diagnosed with a neurological lower urinary tract dysfunction due to either spinal cord injury, Multiple Sclerosis, Parkinson's Syndrome, Cauda equina syndrome Or Diagnosed with bladder outflow obstruction secondary to benign prostate enlargement Or Diagnosed with detrusor underactivity
      • Performing single use clean intermittent self-catheterisation (ISC) at least twice a day
      • Willing to undergo training with GC Trainer video prior to use of catheter
      • Provided fully informed consent and has sufficient understanding of English or French
      • Sufficient dexterity to use GentleCath™ Air for Men intermittent including ability to open packaging
      • Intact urethral sensation of catheterisation
      • Willing to use only the GentleCath™ Air intermittent catheter for the full duration of the study (60-days)
      • Subject has a valid email address so the Investigator can send links to study questionnaires and the subject has access to a web enabled device

Exclusion criteria

Exclusion Criteria:

    • Participation in another related urological study

      • Unable to perform ISC unaided
      • Already prescribed the GentleCath™ Air Intermittent Catheter
      • Absent urethral or perineal sensation
      • Unwilling to undergo training with GC Trainer prior to use of catheter
      • Insufficient dexterity to use GentleCath™ Air Intermittent Catheter and or packaging
      • Suffering from a symptomatic UTI (Urinary Tract Infections) at the time of inclusion or in the preceding 6-weeks
      • Undergoing surgical treatment during the period of the study
      • Performing catheterisation for urethral stricture
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
72 participants (actual)
Patient registry
No

Interventions

  • DeviceIntermittent self-catheterisation

    Self-catheterising with GC Male and Glide Male with Feelclean technology

06

What researchers measure

Primary outcomes

  1. To assess difficulty during catheterisation and quality of life using the ICDQ and ISC-Q validated questionnaires during catheterisation

    To assess difficulty during catheterisation and quality of life using the ICDQ and ISC-Q

    Time frame: 60 days

Secondary outcomes

  1. To assess patient confidence regarding reduced stickiness plus related risk of urethral injury and resultant bleeding or infection

    To assess patient confidence regarding reduced stickiness plus related risk of urethral

    Time frame: 60 days

  2. To assess compliance with the self-catheterization for the study duration

    To assess compliance with the self-catheterization for the study duration

    Time frame: 60 days

07

Study locations

16 sites
  • Kessler Institute for Rehabilitation
    West Orange, New Jersey 07052, United States
  • Trustees of The University of Pennsylvania | Penn Urology Washington Square
    Philadelphia, Pennsylvania 19106, United States
  • Centre Hospitalier Universitaire de Bordeaux | Pellegrin Hospital - Urology Department
    Bordeaux, 33076, France
  • Assistance Publique Hopitaux de Paris | Pitie Salpetriere University Hospital - Urology Department
    Paris, 75013, France
  • Stockport NHS Foundation Trust | Stepping Hill Hospital - Research and Innovation Department
    Stockport, Cheshire SK2 7JE, United Kingdom
  • Broomfield Hospital
    Chelmsford, Essex CM1 7ET, United Kingdom
  • Mid and South Essex NHS Foundation Trust | Southend University Hospital - Research & Development
    Southend-on-Sea, Essex SS0 0RY, United Kingdom
  • Aneurin Bevan University Health Board | Royal Gwent Hospital - Clinical Research Centre
    Newport, Gwent NP20 2UB, United Kingdom
  • Southampton General Hospital
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Kent and Canterbury Hospital | Renal Research Delivery Team
    Canterbury, Kent CT2 7FG, United Kingdom
  • Newcastle upon Tyne Hospitals NHS Foundation Trust | Freeman Hospital - Urology Department
    Newcastle, Newcastle Upon Tyne NE7 7DN, United Kingdom
  • Sunderland Royal Hospital
    Sunderland, Tyne & Wear SR4 7TP, United Kingdom
  • North Bristol NHS Trust | Southmead Hospital - Research and Development - Urology Department
    Bristol, Westbury-on-Trym BS10 5NB, United Kingdom
  • Mid Yorkshire Teaching NHS Trust | Pinderfields Hospital - Yorkshire Regional Spinal Injuries Centre
    Wakefield, Yorkshire WF1 4DG, United Kingdom
  • Guy's and St Thomas' Foundation Trust | Guy's Hospital - Transplant, Renal and Urology Research
    London, SE1 9RT, United Kingdom
  • King's College Hospital NHS Foundation Trust | King's College Hospital - Renal Research Department
    London, SE5 9RS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05470751
Lead sponsor
ConvaTec Inc.
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Feb 2, 2023
Primary completion
Apr 6, 2024
Completion
Apr 6, 2024
Last update
Apr 30, 2024

Study contacts

Chris Harding
principal investigator · Site Investigator - Newcastle

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion